NMS · Biotechnology

ASMB (ASMB) Stock

$26.68 +0.87% NMS: ASMB Healthcare

Valuation

MetricValue
Price$26.68
Market Cap$424.02M
P/E Ratio-51.53
P/B Ratio2.18
P/S Ratio6.33
EPS (TTM)$0.00
52-Week High$39.71
52-Week Low$16.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2.90%
ROA-2.33%
ROCE-5.80%
Gross Margin-16.67%
Operating Margin-16.67%
Net Margin-8.98%
Debt/Equity0.01
Current Ratio5.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$6.0M$0$7.0M$29.0M$72.0M
Operating Profit$-133.0M$-94.0M$-65.0M$-45.0M$-12.0M
Net Profit$-130.0M$-93.0M$-61.0M$-40.0M$-6.0M
EPS$-36.00$-22.82$-13.38$-6.69$-0.55
Op Margin-2121.7%—-902.5%-159.3%-16.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$191.0M$102.0M$137.0M$119.0M$258.0M
Total Liabilities$22.0M$19.0M$96.0M$86.0M$51.0M
Cash$46.0M$52.0M$20.0M$38.0M$58.0M
Borrowings$6.0M$3.0M$2.0M$3.0M$3.0M

Latest News

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead MarketBeat · Jun 8, 2026 Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands MarketBeat · Jun 5, 2026 Assembly Biosciences Announces Upcoming Investor Conference Presentations GlobeNewswire · May 28, 2026 Assembly Biosciences Closes Securities Offering MT Newswires · May 26, 2026 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-93.0M$-84.0M$23.0M$-51.0M$-41.0M
Investing Cash Flow$23.0M$91.0M$-69.0M$40.0M$-114.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-14.0M$7.0M$-33.0M$19.0M$20.0M
Free Cash Flow$-96.0M$-85.0M$22.0M$-51.0M$-41.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.84%
Quick Ratio6.65
Interest Coverage—
Return 1Y37.59%
Return 3Y91.06%
Return 5Y-34.29%

Ownership

Insiders Held28.42%
Institutions Held48.46%
Institutions Float Held67.70%
Institutional HolderSharesReport Date
Gilead Sciences Inc4,505,3912026-03-31
Farallon Capital Management LLC1,227,5902026-03-31
RA Capital Management, L.P.1,020,4102026-03-31
Commodore Capital Lp1,000,0002026-03-31
Janus Henderson Group PLC849,3092026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%
IMRX $4.24 -2.75% -3.94 $153.92M 0.00%

About ASMB

ASMB is led by CEO Jason A. Okazaki, employs 73 people, headquartered in US, publicly traded since 2010.

ASMB stock trades at $26.68 with a market capitalization of $424.02M. The stock is valued at a price-to-earnings (P/E) ratio of -51.53, price-to-book of 2.18, price-to-sales of 6.33. Over the past 52 weeks the stock has ranged between $16.80 and $39.71, and currently trades 32.8% below its 52-week high.

On profitability, ASMB generates a return on equity (ROE) of -2.90%, return on capital employed of -5.80%, an operating margin of -16.67%, a net profit margin of -8.98%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides